A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Basit Öğe Kaydı
dc.authoridYasar, Hatime/0000-0002-0545-1383
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorOzturk, Akin
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorCicin, Irfan
dc.contributor.authorPaydas, Semra
dc.date.accessioned2024-10-29T17:58:40Z
dc.date.available2024-10-29T17:58:40Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractTo evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.
dc.identifier.doi10.1097/MD.0000000000037972
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue21en_US
dc.identifier.pmid38787994
dc.identifier.scopus2-s2.0-85194219961
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000037972
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14442
dc.identifier.volume103
dc.identifier.wosWOS:001230616700060
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectImaging Characteristics
dc.subjectGene Rearrangement
dc.subjectAdenocarcinomas
dc.subjectManagement
dc.subjectFusion
dc.titleA multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu